SCHEMBL3753138

SCHEMBL3753138

O=C1CCc2ccccc2C1Cc1ccc2ccccc2c1

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.42
HTR2A P28223 1/20 0.42
SIGMAR1 Q99720 1/20 0.42
CYP1A2 P05177 2/20 0.38
CYP2A6 P11509 1/20 0.38
HCRTR1 O43613 2/20 0.37
HCRTR2 O43614 2/20 0.37
MC4R P32245 1/20 0.37
MC5R P33032 1/20 0.37
MC3R P41968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6823296 0.82 HTR2A (0.50) RETHTR2A
SCHEMBL6823777 0.79 HTR2A (0.45) RETHTR2A
SCHEMBL3753380 0.74 ALDH1A1 (0.54) RETHTR2ACYP1A2
SCHEMBL6826748 0.72 SLC6A2 (0.40) RETHTR2A
SCHEMBL1870242 0.72 HTR2A (0.53) RETHTR2A
SCHEMBL3920414 0.71 MAPT (0.41)
SCHEMBL15610746 0.71 PRCP (0.68)
SCHEMBL16473206 0.70 GRIN2B (0.39)
SCHEMBL7331623 0.70 ANPEP (0.42) HTR2ASIGMAR1
SCHEMBL7926695 0.69 HTR2A (0.50) RETHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838130-B2 Aminodibenzofluorene derivative and organic electroluminescence device using the same IDEMITSU KOSAN CO., LTD. (JP) 2010-11-23 US disclosed
US-20090267491-A1 AMINODIBENZOFLUORENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME IDEMITSU KOSAN CO., LTD. (JP) 2009-10-29 US disclosed
EP-1119543-B1 N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR ORTHO MCNEIL PHARM INC (US) 2004-12-15 EP disclosed
EP-1119543-A1 N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR Ortho-McNeil Pharmaceutical, Inc. (US) 2001-08-01 EP disclosed
US-6201025-B1 FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS ORTHO-MCNEIL PHARMACEUTICAL, INC. 2001-03-13 US disclosed
WO-2000020376-A1 N-ARALKYLAMINOTETRALINS AS LIGANDS FOR THE NEUROPEPTIDE Y Y5 RECEPTOR ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2000-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090267491-A1 AMINODIBENZOFLUORENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME L1CAM, DDC, LEF1 RET 1504/4885HTR2A 3767/4885SIGMAR1 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.